Xequel Bio To Present Corporate Overview and Clinical Trial Data at Eyecelerator® at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting - Presentation Will Highlight Positive Clinical Trial Data on iNexin™ for Treatment of Corneal Injury - - Xequel Launches New Corporate Website with Focus on Novel Peptide Platform for Ophthalmology,...

Xequel Bio Expands Leadership Team with Appointments of Dr. Michael J. Brubaker as Chief Scientific Officer and Tony C. Tipton as Chief Operating Officer CHARLESTON, S.C. and FORT WORTH, Texas, July 26, 2022 (GLOBE NEWSWIRE) -- Xequel Bio, Inc., a clinical stage biopharmaceutical company developing dermatologic and ophthalmic therapeutics utilizing...

Xequel Bio Announces Positive Results from Phase 1b Study of iNexin™, a Novel aCT1 Ophthalmic Solution Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance to Phase 2 Proprietary aCT1 Platform to Address Unmet...

Xequel Bio, Inc. Appoints Veteran Pharmaceutical Executives to Advance Next Stage of Corporate Growth - Jerry St. Peter Named Chief Executive Officer and Member of the Board of Directors- Wes Brazell Named Chief Financial Officer- Executives Bring Significant Global Biopharmaceutical Development and...